Tenax Research Development vs Income Tax Expense Analysis

TENX Stock

USD 6.01 0.07 1.18%

Tenax Therapeutics financial indicator trend analysis is much more than just breaking down Tenax Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tenax Therapeutics is a good investment. Please check the relationship between Tenax Therapeutics Research Development and its Income Tax Expense accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Research Development vs Income Tax Expense

Research Development vs Income Tax Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tenax Therapeutics Research Development account and Income Tax Expense. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Tenax Therapeutics' Research Development and Income Tax Expense is -0.36. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Tenax Therapeutics, assuming nothing else is changed. The correlation between historical values of Tenax Therapeutics' Research Development and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Tenax Therapeutics are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Research Development i.e., Tenax Therapeutics' Research Development and Income Tax Expense go up and down completely randomly.

Correlation Coefficient

-0.36

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Research Development

Income Tax Expense

Most indicators from Tenax Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tenax Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.At this time, Tenax Therapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 0.49 in 2024, whereas Selling General Administrative is likely to drop slightly above 4.9 M in 2024.

	2021	2022	2023	2024 (projected)
Other Operating Expenses	32.7M	11.1M	8.2M	8.4M
Depreciation And Amortization	109.0K	113.3K	7.6K	7.2K

Other Operating Expenses Depreciation And Amortization

Tenax Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Common Stock Total Equity	Property Plant And Equipment Gross	Non Currrent Assets Other	Property Plant Equipment	Other Assets	Long Term Debt
Total Assets		-0.22	0.19	0.13	1.0	-0.17	-0.99	0.27	-0.14	0.99	0.76	1.0	0.34	0.91	-0.13	0.11	0.89	1.0	0.26	-0.19	-0.19	-0.2	-0.53	-0.39	0.02	-0.31
Short Long Term Debt Total	-0.22		-0.04	-0.04	-0.26	0.72	0.28	0.33	-0.03	-0.23	-0.13	-0.25	-0.2	0.17	-0.17	-0.43	0.16	-0.25	-0.22	-0.1	-0.1	0.73	0.09	0.35	-0.16	0.56
Other Current Liab	0.19	-0.04		0.83	0.16	-0.2	-0.14	0.05	-0.13	0.14	0.33	0.16	-0.07	0.11	-0.17	0.01	0.38	0.16	-0.17	-0.18	-0.18	-0.18	-0.06	-0.35	0.05	-0.06
Total Current Liabilities	0.13	-0.04	0.83		0.11	-0.29	-0.1	-0.19	0.36	0.1	0.16	0.1	0.3	0.01	0.31	0.25	0.34	0.11	-0.03	-0.33	-0.33	-0.23	0.02	-0.27	-0.16	0.02
Total Stockholder Equity	1.0	-0.26	0.16	0.11		-0.2	-1.0	0.25	-0.14	0.99	0.76	1.0	0.34	0.9	-0.12	0.13	0.87	1.0	0.27	-0.18	-0.18	-0.23	-0.53	-0.4	0.03	-0.33
Property Plant And Equipment Net	-0.17	0.72	-0.2	-0.29	-0.2		0.2	0.46	-0.31	-0.17	-0.07	-0.2	-0.26	0.17	-0.47	-0.56	0.11	-0.2	-0.22	0.14	0.14	0.98	0.03	0.52	0.08	0.6
Net Debt	-0.99	0.28	-0.14	-0.1	-1.0	0.2		-0.22	0.1	-1.0	-0.74	-1.0	-0.36	-0.88	0.09	-0.16	-0.85	-1.0	-0.28	0.19	0.19	0.24	0.52	0.39	-0.01	0.34
Retained Earnings	0.27	0.33	0.05	-0.19	0.25	0.46	-0.22		-0.53	0.24	0.28	0.23	-0.19	0.47	-0.62	-0.93	0.39	0.23	-0.27	0.6	0.6	0.37	-0.18	0.27	0.67	0.45
Accounts Payable	-0.14	-0.03	-0.13	0.36	-0.14	-0.31	0.1	-0.53		-0.11	-0.38	-0.12	0.74	-0.24	0.82	0.52	-0.11	-0.11	0.05	-0.31	-0.3	-0.22	0.23	-0.05	-0.42	-0.19
Cash	0.99	-0.23	0.14	0.1	0.99	-0.17	-1.0	0.24	-0.11		0.75	1.0	0.35	0.91	-0.1	0.13	0.87	1.0	0.27	-0.19	-0.19	-0.2	-0.53	-0.37	0.01	-0.32
Non Current Assets Total	0.76	-0.13	0.33	0.16	0.76	-0.07	-0.74	0.28	-0.38	0.75		0.75	-0.18	0.71	-0.27	0.0	0.72	0.75	0.16	-0.12	-0.12	-0.14	-0.66	-0.37	0.17	-0.19
Cash And Short Term Investments	1.0	-0.25	0.16	0.1	1.0	-0.2	-1.0	0.23	-0.12	1.0	0.75		0.34	0.9	-0.12	0.14	0.87	1.0	0.26	-0.21	-0.21	-0.23	-0.53	-0.41	0.0	-0.34
Common Stock Shares Outstanding	0.34	-0.2	-0.07	0.3	0.34	-0.26	-0.36	-0.19	0.74	0.35	-0.18	0.34		0.2	0.57	0.34	0.29	0.35	0.21	-0.18	-0.18	-0.2	0.05	-0.14	-0.23	-0.28
Non Current Liabilities Total	0.91	0.17	0.11	0.01	0.9	0.17	-0.88	0.47	-0.24	0.91	0.71	0.9	0.2		-0.31	-0.14	0.94	0.9	0.12	-0.18	-0.18	0.14	-0.5	-0.25	0.0	-0.06
Other Current Assets	-0.13	-0.17	-0.17	0.31	-0.12	-0.47	0.09	-0.62	0.82	-0.1	-0.27	-0.12	0.57	-0.31		0.62	-0.19	-0.1	0.51	-0.23	-0.22	-0.39	0.15	0.08	-0.31	-0.26
Other Stockholder Equity	0.11	-0.43	0.01	0.25	0.13	-0.56	-0.16	-0.93	0.52	0.13	0.0	0.14	0.34	-0.14	0.62		-0.07	0.15	0.37	-0.68	-0.68	-0.48	-0.02	-0.42	-0.67	-0.58
Total Liab	0.89	0.16	0.38	0.34	0.87	0.11	-0.85	0.39	-0.11	0.87	0.72	0.87	0.29	0.94	-0.19	-0.07		0.87	0.13	-0.27	-0.27	0.09	-0.46	-0.29	-0.04	-0.02
Total Current Assets	1.0	-0.25	0.16	0.11	1.0	-0.2	-1.0	0.23	-0.11	1.0	0.75	1.0	0.35	0.9	-0.1	0.15	0.87		0.27	-0.21	-0.21	-0.23	-0.52	-0.41	-0.01	-0.34
Short Term Debt	0.26	-0.22	-0.17	-0.03	0.27	-0.22	-0.28	-0.27	0.05	0.27	0.16	0.26	0.21	0.12	0.51	0.37	0.13	0.27		0.04	0.03	-0.23	-0.16	0.27	0.05	-0.36
Common Stock	-0.19	-0.1	-0.18	-0.33	-0.18	0.14	0.19	0.6	-0.31	-0.19	-0.12	-0.21	-0.18	-0.18	-0.23	-0.68	-0.27	-0.21	0.04		1.0	0.03	0.06	0.63	0.95	0.06
Common Stock Total Equity	-0.19	-0.1	-0.18	-0.33	-0.18	0.14	0.19	0.6	-0.3	-0.19	-0.12	-0.21	-0.18	-0.18	-0.22	-0.68	-0.27	-0.21	0.03	1.0		0.03	0.06	0.62	0.95	0.06
Property Plant And Equipment Gross	-0.2	0.73	-0.18	-0.23	-0.23	0.98	0.24	0.37	-0.22	-0.2	-0.14	-0.23	-0.2	0.14	-0.39	-0.48	0.09	-0.23	-0.23	0.03	0.03		0.15	0.48	-0.04	0.61
Non Currrent Assets Other	-0.53	0.09	-0.06	0.02	-0.53	0.03	0.52	-0.18	0.23	-0.53	-0.66	-0.53	0.05	-0.5	0.15	-0.02	-0.46	-0.52	-0.16	0.06	0.06	0.15		0.22	-0.1	0.14
Property Plant Equipment	-0.39	0.35	-0.35	-0.27	-0.4	0.52	0.39	0.27	-0.05	-0.37	-0.37	-0.41	-0.14	-0.25	0.08	-0.42	-0.29	-0.41	0.27	0.63	0.62	0.48	0.22		0.48	0.31
Other Assets	0.02	-0.16	0.05	-0.16	0.03	0.08	-0.01	0.67	-0.42	0.01	0.17	0.0	-0.23	0.0	-0.31	-0.67	-0.04	-0.01	0.05	0.95	0.95	-0.04	-0.1	0.48		0.0
Long Term Debt	-0.31	0.56	-0.06	0.02	-0.33	0.6	0.34	0.45	-0.19	-0.32	-0.19	-0.34	-0.28	-0.06	-0.26	-0.58	-0.02	-0.34	-0.36	0.06	0.06	0.61	0.14	0.31	0.0

Click cells to compare fundamentals

Tenax Therapeutics Account Relationship Matchups

Tenax Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.4M	6.9M	6.0M	3.4M	11.7M	15.5M
Other Current Liab	760.0K	1.2M	597.1K	655.7K	1.0M	790.7K
Total Current Liabilities	2.5M	2.1M	1.6M	1.8M	3.6M	3.8M
Total Stockholder Equity	3.8M	4.6M	4.2M	1.5M	8.1M	12.7M
Property Plant And Equipment Net	8.5K	176.0K	64.8K	294.8K	186.7K	0.0
Net Debt	(4.7M)	(5.9M)	(5.3M)	(1.3M)	(9.3M)	(9.8M)
Retained Earnings	(236.2M)	(246.0M)	(278.5M)	(289.5M)	(297.3M)	(282.4M)
Accounts Payable	1.7M	757.9K	859.6K	448.4K	2.1M	2.2M
Cash	4.9M	6.3M	5.6M	2.1M	9.8M	9.6M
Non Current Assets Total	184.4K	73.2K	303.2K	196.2K	1.1K	1.1K
Cash And Short Term Investments	5.4M	6.7M	5.6M	2.1M	9.8M	10.0M
Common Stock Shares Outstanding	309.8K	6.5K	12.9K	18.4K	248.4K	260.9K
Liabilities And Stockholders Equity	6.4M	6.9M	6.0M	3.4M	11.7M	15.5M
Non Current Liabilities Total	749.8K	60.4K	124.2K	183.6K	64.2K	0.0
Other Current Assets	781.0K	82.6K	105.1K	1.1M	1.9M	2.0M
Other Stockholder Equity	239.9M	250.6M	282.7M	291.0M	305.4M	320.6M
Total Liab	2.6M	2.2M	1.7M	1.9M	3.6M	2.8M
Total Current Assets	6.2M	6.8M	5.7M	3.2M	11.7M	10.5M
Common Stock	674.0	1.3K	2.5K	4.6K	30.0	28.5
Common Stock Total Equity	141.0	379.0	674.0	1.3K	1.1K	1.1K
Property Plant And Equipment Gross	8.5K	176.0K	6.0K	294.8K	186.7K	0.0
Accumulated Other Comprehensive Income	(16.2K)	516.0	458.0	(70.0)	(63.0)	(66.15)
Property Plant Equipment	8.5K	6.6K	64.8K	294.8K	265.3K	172.3K
Net Tangible Assets	11.8M	3.8M	4.6M	4.2M	3.8M	3.6M
Retained Earnings Total Equity	(213.5M)	(227.8M)	(236.2M)	(246.0M)	(221.4M)	(232.5M)
Capital Surpluse	222.4M	239.6M	239.9M	250.6M	288.2M	226.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tenax Research Development vs Income Tax Expense Analysis

Research Development vs Income Tax Expense

Research Development vs Income Tax Expense Correlation Analysis

Correlation Coefficient

Research Development

Income Tax Expense

Tenax Therapeutics fundamental ratios Correlations

Tenax Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tenax Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Tenax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Other Stockholder Equity	- 0.93	Retained Earnings